FDA approved the first U.S. plasmid DNA immunotherapy—to reduce repeat surgeries.
Voceryq received accelerated approval for adults with recurrent respiratory papillomatosis; confirmatory trials are still required.
The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis, a rare HPV-driven disease that can force patients into repeated airway surgeries. It is the first plasmid DNA-based immunotherapy approved in the United States.
WHAT HAPPENED
Voceryq delivers two plasmids intended to train an immune response against HPV types 6 and 11 and is administered by injection with electroporation. In the open-label multicenter study, seven of 26 patients who had needed at least three baseline surgeries required no surgical intervention during the first year after treatment. The approval is specifically to reduce the frequency of surgical papilloma excisions.
WHY THIS IS HOPESLOP
For a disease measured in surgeries patients have to repeat, even a credible path toward fewer procedures matters. The hope here is precise: an approved new option, a meaningful signal, and a promise that still has to survive confirmatory evidence.
ORIGINAL SOURCEU.S. Food and Drug AdministrationRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.
MORE HOPESLOP
The first 1,000 native trees took root along the Guadalupe River.
The locally collected seedlings begin a five-year, 50,000-tree recovery plan.
Two Kauaʻi state parks reopened after two months of hurricane repairs.
Major lookouts and several trails are open again, though repairs and closures continue.
Virginia voters approved an equal-marriage amendment.
The result reverses a 2006 state constitutional ban; certification is still pending.